Human ALK-1 / ACVRL1 Protein, His Tag

Source : 

Human ALK-1, His Tag (AL1-H5227) is expressed from human 293 cells (HEK293). It contains AA Asp 22 - Gln 118 (Accession # NP_000011.2).

 

Molecule : ALK-1

 

Synonyms : ACVRL1,ACVRLK1,ALK-1,HHT,HHT2,ORW2,SKR3,TSR-I

 

Format : Powder

 

Category : Bio-Markers & CD Antigens

 

Accession : NP_000011.2

 

Storage : -20℃

 

Shipping condition : Powder,RT

 

Molecular Weight : 11.5 kDa

 

Characteristics :

This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 11.5 kDa. The protein migrates as 22-28 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : PBS, pH7.4

 

Description :

Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.

 

References :

(1) Ten Dijke P, Ichijo H, et al.,1993, Oncogene 8 (10): 2879–87.
(2) Johnson DW, Berg JN, et al., 1996, Nat Genet 13 (2): 189–95.
(3) Lawlor MW, Read BP, et al., 2011, Am J Pathol. 178(2):784-93.
(4) Mitchell D,et al., 2010, Mol Cancer Ther.. 9(2):379-88.